Question · asked by 1 review
Vasodilator vs Placebo or no active treatment: Maximal mouth opening (interincisal distance)
- Population
- People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
- Intervention
- Vasodilator
- Comparison
- Placebo or no active treatment
- Outcome
- Maximal mouth opening (interincisal distance)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Vasodilators (isoxsuprine, xanthinol nicotinate) vs Placebo or no active treatment Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) · 3 to 6 months It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty). Interventions for managing oral submucous fibrosis (2024) · Cochrane All outcomes | MD 4.04 [-1.93, 10.02] | 2 studies · 85 participants | Very low |
Vasodilators (isoxsuprine, xanthinol nicotinate) vs Placebo or no active treatment Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) · Less than 3 months It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty). Interventions for managing oral submucous fibrosis (2024) · Cochrane All outcomes | MD 2.51 [-0.99, 6.01] | 2 studies · 85 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes | 2022-09 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.